Three decades ago, Greg Cowan was grafting as a painter and decorator and could only dream of playing to thousands of idolising fans in Europe and Japan.
Outcasts star Greg Cowan on making music during the dark days of the Troubles
↧
↧
Fires Continue to Ravage Greece Amid Europe’s Protracted Heat Wave
Multiple countries are sending firefighting aid to Greece as blazes rage for a sixth day.
↧
As wildfires rage, milestone report expected to deliver 'starkest warning yet' on climate crisis
As wildfires rage across southern Europe and parts of the US, the biggest climate change report in almost a decade is set to deliver the "starkest warning yet" about the crisis facing the planet.
↧
Noxopharm set for busy six months ahead with strong news flow expected from drug pipeline
Noxopharm Ltd (ASX:NOX) is set for a very busy six months ahead with news flow expected from its Veyonda® immune-oncology drug that works with the body’s defence mechanisms to fight cancer cells. The clinical-stage drug development company is targeting Veyonda® to become a standard go-to drug to boost the effectiveness of a range of anti-cancer therapies such as radiation treatment and chemotherapy. It has an exciting pipeline of drugs under development and believes that its novel technology platform is “one of the most exciting and valuable platforms” in the pharmaceutical industry. News flow ahead Noxopharm chief executive officer Graham Kelly said the company was into some of the latest and most active areas of interest by the pharmaceutical industry - areas spanning cancer, chronic inflammatory diseases and autoimmune disorders. “The result is an exciting pipeline of drugs now under development within Noxopharm that you will be hearing more about over coming months.” Currently, Noxopharm remains focused on its 4-pillars oncology program. In the next six months, the company is looking forward to the start of patient recruitment for its IONIC-1 (checkpoint inhibitor therapy), DARRT-2 (radiotherapy) and CEP-2 (chemotherapy) programs for its Veyonda® anti-cancer drug candidate. Describing the drug as a cancer treatment enhancement, Veyonda has multiple mechanisms of action that boost the effectiveness of other standard anti-cancer therapies. It is also targeting the completion of the COVID-19 clinical trial and progressing its novel drug pipeline in the coming six months. Pharmorage, a wholly-owned subsidiary in partnership with the Hudson Institute of Medical Research and in collaboration with The Australian National University, is also progressing novel drug development for chronic inflammation and autoimmunity. Significantly de-risked The company highlighted how it is significantly de-risked as it is targeting areas of major medical need and industry interest. It has multiple shots at the goal-post and is not limited to a single therapeutic field. Noxopharm’s aim is to assist in existing therapies and not rely on the test drug carrying the full load. 4-pillars oncology program The 4-pillars oncology program is Noxopharm’s signature clinical program, aiming to prove that Veyonda® can make other common forms of anti-cancer therapy work better. It is testing Veyonda® in the following combinations: Noxopharm has said this was a completely new concept in cancer therapy, made possible only because of a unique collection of anti-cancer functions possessed by idronoxil, the active ingredient in Veyonda®. Where almost all other anti-cancer drugs operate through a single or very limited specific mechanisms, idronoxil targets a range of tricks employed by cancer cells to resist treatments ranging from the old standards, chemotherapy to radiotherapy, to the new checkpoint inhibitor drug therapies. From stopping cancer cells dividing, to blocking cellular repair mechanisms, to increasing immune cell trafficking, to killing cancer cells outright, idronoxil is a unique multi-purpose, cancer-fighting molecule. Key European patent allowance In late June 2021, the company secured a crucial European patent allowance for Veyonda®. The European Patent Office issued a formal Notice of Allowance of claims for patent application number 17778482.4, indicating an intention to move to the patent grant stage. Noxopharm believes the patent allowance bodes well for related Veyonda® patent applications in Europe and other important territories such as the US. CEO Graham Kelly said: “This allowance is very pleasing validation of our strategy of building a strong IP position around Veyonda® based on a series of inter-connected patents. “The interconnection is between method of administration and clinical use and removes the reliance on the strength of any single patent. “A granted patent also will help underpin our commercial aim of Veyonda® becoming a standard of care drug in combination with other major forms of cancer therapy.” The patent will run through to April 2037. It is also not limited to a particular cancer type, should cover the treatment of any cancer and can be administered to patients who have received or are receiving chemotherapy or radiotherapy. Phase 2 trial for DARRT-2 study The company is also moving ahead for the Phase Two trial of Veyonda® for its upcoming DARRT-2 study. This week NOX secured Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its DARRT-2 multi-national clinical study, paving the way for the trial to kick off in the United States. The green light marks the second IND classification granted to cover the administration of Noxopharm’s anti-cancer drug candidate, Veyonda®, in US cancer patients. So far, two prominent US cancer centres have volunteered to participate in the DARRT-2 study, which will take place over as many as 15 trial sites across Australia, France, Hungary and the United States and involve around 100 patients. Specifically, the US’ largest and top-ranked comprehensive oncology institution, the Texas-based MD Anderson Cancer Center, and Los Angeles’ Beverly Hills Cancer Center sought to participate in the clinical trial and will serve as the study’s US sites. DARRT-2 will involve around 100 patients with progressive, metastatic prostate, breast or lung cancers that have failed standard treatment options and are eligible for low-dose, palliative external beam radiotherapy (RT) to a single lesion. The clinical-stage drug development company will utilise a higher dose of its Veyonda® drug candidate to generate the phenomenon of the abscopal response in cancer patients. Building on the successful results of DARRT-1, DARRT-2 will be a much bigger study and will explore a more intensive treatment with Veyonda®. Noxopharm chief medical officer Dr Gisela Mautner “To increase the value of the study, we have added a second trial arm to include a small number of breast and lung cancer patients. “This will ensure that, apart from the main focus of the study in prostate cancer, we also will generate results in two additional cancer types.” COVID-19 beneficiary Noxopharm has produced not only a drug capable of restoring cancer-fighting immune function in a cancer patient, but the same drug could also potentially block an inappropriately excessive immune system in a patient infected with SARS-C0V-2 virus. The STING signalling pathway is a forward scout that detects the presence of damage in the body and triggers an immune response. COVID-19 patients who fall into septic shock mostly do so because their STING response has gone into overdrive. Veyonda® blocks the STING response and Noxopharm is now testing the ability of Veyonda® to prevent the acute consequences of septic shock in COVID-19. LuPIN program The LuPIN program is the first of the 4-pillars program to reach Phase-2 level. Noxopharm is set to benefit from Novartis’ VISION study featuring its experimental drug, 177Lutetium-PSMA-617 (Lu-PSMA-617), which looks set to become an important new treatment for late-stage prostate cancer, based on the Phase 3 clinical trial data. The study reported a median overall survival (mOS) of 15.3 months for Lu-PSMA-617 + standard of care versus 11.3 months for standard of care alone. This compares with 19.7 months from the LuPIN trial that tested the combination of Lu-PSMA-617 and Veyonda® in men with end-stage mCRPC, who had progressed on at least three previous lines of therapy. This is strong encouragement for Noxopharm, given its recent LuPIN trial data showing even stronger survival outcome when the experimental radioligand Lu-PSMA-617 is combined with Veyonda®. Dr Kelly said the news confirms that Veyonda® in combination with Lu-PSMA-617 provides a considerable survival advantage over Lu-PSMA-617 alone. “The LuPIN mOS outcome of 19.7 months still remains the best survival outcome of any drug approved for use in men with end-stage prostate cancer including enzalutamide, abiraterone, docetaxel, cabazitaxel and now Lu-PSMA-617. He said having Lu-PSMA-617 likely to come to market as a third-line therapy provides a clear development pathway now for Veyonda® to come to market itself, with a distinct opportunity to make the Veyonda®/Lu-PSMA-617 combination a new standard of care for end-stage prostate cancer.” Commercial end-point for Veyonda® Noxopharm prepared to take Veyonda all the way to market but given that it is a general booster of most forms of cancer therapy, a partnership is potentially more likely. A commercial transaction is seen as potentially likely in the current Phase 2 trialling.
↧
Europe on a geopolitical fault line
(MENAFN - Jordan Times) MADRID – Two months ago, in his–address–to the United Nations General Assembly, UN Secretary-General–Ant–nio Guterres–expressed his fear that a–Great Fracture– could split the international order into two–separate and competing...
↧
↧
Paradigm Biopharmaceuticals' pre-clinical food study in chronic heart failure continues ahead of commentary in Q4
Paradigm Biopharmaceuticals Ltd (ASX:PAR) will be heavily focused on its Phase 3 trial of its osteoarthritis treatment Zilosul® in 2021, its chief operating officer Jeannie Joughin told Proactive. The company presented at the 39th annual JP Morgan Healthcare Conference this week, outlining a roadmap that will take the business through to the middle of 2024. It is confident it will make an Investigational New Drug (IND) submission with the US Food and Drug Administration by the end of this quarter, following positive feedback from its Type-C meeting with the FDA in December that gave the green light to the next phase. In an interview with Proactive, Joughin said 2021 would see the beginning of the Phase 3 trial of Zilosul®, following a year of positive progress in 2020. “We are confident we will commence the first of two pivotal studies, dosing the first US patient, by June,” she said. Prep work all done Paradigm spent a fair chunk of 2020 de-risking Zilosul® by seeking as much feedback from international regulatory bodies as possible. It will use the same clinical trial protocol in the US, Europe and Australia, potentially enabling registrations in multiple jurisdictions, saving time and money. “The feedback we gathered not just from the FDA, but also from several meetings with European regulators, means we have a globally harmonised protocol for Zilosul®,” Joughin said. Minimum effective dose Joughin said the regulatory bodies had asked Paradigm to investigate the lowest possible dosage of Zilosul® it could give to patients without compromising on efficacy, and this would be a focus of the Phase 3 trial. Paradigm already has a wealth of Phase 2b data that confirms the effectiveness of Zilosul®, which is the company’s name for injected pentosan polysulphate sodium, a drug with a long history of use and a well-established safety profile. Zilosul® has been shown to decrease pain, increase function and reduce the volume of bone marrow edema-like lesions in osteoarthritis patients’ knees. “A focus of the Phase 3 trials will be to find out how little of it we can give to a patient and for it to remain effective,” Joughin said. The market A key focus of the company’s presentation at the JP Morgan conference was to outline the interest in finding effective treatments for osteoarthritis. Some of the biggest names in pharma, such as Pfizer, Sanofi, Mitsubishi Tanabe, MundiPharma and Galápagos, have made big-money plays for osteoarthritis treatments. But Joughin says Paradim’s Zilosul® had an advantage over many of the drugs being investigated by big pharma – its multiple modes of action. “There is a huge unmet need, with some 72 million people with osteoarthritis in the US, Canada, Australia and the top five European countries alone,” she said. “And that is only people who have been clinically diagnosed, the number could be much higher. “Many people are unsatisfied with the current available treatments. As the disease progresses, opioids are really the only thing on offer, and many young people suffering from the disease don’t want replacements. “The pie is enormous, but many of the treatments being investigated are looking at only a single mode of action – perhaps they’re looking only at the inflammation aspect of osteoarthritis, or the pain aspect, or the cartilage loss aspect. “Zilosul® tackles these three and also improves blood flow through self-adhesion molecules that target capitally endothelial cells that display anti-thrombotic effects.” There are a whopping 81 per cent of osteoarthritis patients dissatisfied with current treatments, and Paradigm is targeting 10 per cent of that market, with Zilosul’s indicative price of US$2,500 per year. The first trial readout for the Phase 3 trial is due to take place in quarter one of 2023, followed by a final readout in quarter three of 2023. The company has a market cap of approximately $544.3 million and shares in the last 12 months have traded in the range of $1.08 to $4.50. - Daniel Paproth
↧
Imugene ends June 2021 quarter with $29.5m cash balance and strong focus on research and development
Imugene Limited (ASX:IMU) (OTCMKTS:IUGNF) is well-funded and ready to progress to human studies for its CF33 and PD1-Vaxx treatments in the near-term as well as continuing enrolment into the HER-Vaxx phase two study. In September the company boosted its balance sheet with a $5.7 million option underwriting agreement which provides holders with an option to purchase shares in the company at 2.6 cents per share. There are currently 217,462,548 Imugene options which are due to expire on November 30, 2020. The agreement further strengthens the company’s financial position building on the existing cash balance of $30.1 million as of June 30, 2020. Funds raised from the issue of options are expected to support the company’s four continuing clinical programs with CF33, PD1- Vaxx and HER-Vaxx as well as provide funding for IP and milestone payments and working capital. CF33 clinical development In the recent annual report, Imugene executive chairman Paul Hopper said the company had experienced “significant change and growth” with the acquisition of an important oncolytic virus program from the City of Hope Cancer Centre (COH) in Los Angeles. He said: “COH oncolytic virus (OV) technology acquisition in November has firmly positioned Imugene in this exciting area of immuno-oncology and we are well advanced in our strategy, notwithstanding the challenges posed by COVID-19, to commence two Phase 1 clinical trials with one study in triple negative breast cancer and another in advanced solid tumors.” CF33 is a chimeric vaccinia poxvirus from the lab of Professor Yuman Fong, chair of surgery at City of Hope, and a noted expert in the oncolytic virus field which utilises naturally occurring or genetically modified viruses to infect, replicate in, and kill cancer cells, while sparing healthy cells. Hopper said: “The relationship with the technology founder Professor Yuman Fong and his team at COH is highly productive and is a source of deep scientific and technical knowledge and expertise for Imugene. “An OV Scientific Advisory Board (SAB) was established at the end of 2019 and we are privileged to have recruited a team of highly eminent OV scientists to the SAB led by Professor Fong as Chairman. “We warmly welcome Professor Prasad Adusumilli of Memorial Sloan Kettering Cancer Centre in New York and Professor Rebecca Auer of Ottawa Hospital to the SAB.” PD1-Vaxx trials In August, Imugene received Human Research Ethics Committee (HREC) approvals to commence a Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx in Australia. This confirms that Imugene has completed all the necessary pre-clinical safety and efficacy testing of PD1-Vaxx required to begin human clinical trials which will target non-small cell lung cancer (NSCLC), the most common type of lung cancer, accounting for around 80% of cases. Hopper said: “PD1-Vaxx, our B-cell check point inhibiting vaccine is in advanced stages of planning for a Phase 1 clinical study in lung cancer and we expect to open the study in Australia before Christmas.” The study is planned to begin in the second half of 2020 and is to be conducted at up to 6-10 sites in North America and Australia under a US Food & Drug Administration (FDA) Investigational New Drug (IND) application. HER-Vaxx phase two trial During the year, management continued to monitor the enrolment and data collection for the HER-Vaxx Phase 2 clinical trial for HER2-positive gastric cancer. Phase 1b study met all key endpoints to identify the optimal dose of HER-Vaxx for the Phase 2 study, confirmed safety and obtained additional immunological data. Hopper said: “HER-Vaxx, our Phase 2 gastric cancer vaccine continues to recruit patients to the study across centres in Eastern Europe and India.” VAXinia and CHECKvacc Additionally, the company received guidance from the US FDA in August on the development pathway for oncolytic virotherapy, VAXinia. The company plans to conduct a first in human Phase 1, open-label, non-randomised, dose-escalating, multi-centre study of VAXinia (CF33+hNIS) for patients with advanced melanoma, head & neck, TNBC, non- small cell lung, bladder, gastric, colorectal and renal cell carcinoma refractory to standard therapy or for which no standard therapy exists. The company is also planning to conduct a first in human Phase I, openlabel, non-randomised, dose-escalation, single centre study of intratumoral (IT) administration of CHECKvacc (CF33+hNIS+antiPD-L1), in patients with metastatic TNBC tumors refractory to standard therapy or for which no standard therapy exists and who have injectable lesions. Patent granted In early October the company received a Notice of Grant from the US Patent and Trademark Office for Patent Application 16/292032, which protects its cancer growth factor immunotherapy platform. The patent titled 'HER-1, HER-3 and IGF-1R composition and uses thereof' protects the method of composition and method of use of Imugene’s Ohio State University licensed vaccines from the laboratory of Professor Pravin Kaumaya. Attaining the US patent is an important milestone for the company and adds extra value to Imugene’s portfolio of B-cell immunotherapies.
↧
Chimeric Therapeutics accelerates development of CAR T therapy as it looks to boost pipeline with additional therapies
Chimeric Therapeutics Ltd (ASX:CHM) is rapidly accelerating the development of its chlorotoxin CAR T therapy (CLTX CAR T) cell therapy as it looks for additional therapies to bring into its pipeline. The clinical-stage biotech company is looking at more curative therapies for patients with cancer, and not just therapies that delay disease progression. Chimeric Therapeutics chief operating officer Jennifer Chow said: “The company is now focused on its pipeline because we do believe that by building out a bigger pipeline or a stronger pipeline with additional assets that have the same type of promise to patients, we're actually going to be able to help more patients in the long term.” Chimeric’s CAR T cell therapy uses a unique tumour-targeting domain – deathstalker scorpion venom – to look specifically for glioblastoma cells, the most fatal brain cancer (GBM). CLTX CAR T-cells utilise chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumour-targeting component of the Chimeric antigen receptor (CAR), which is programmed to seek out an antigen on a tumour and kill it, effectively leveraging on the patient’s own cells to treat the cancer. The therapy is a novel immunotherapy that has the potential to extend the range of solid tumours targetable by CAR T cells and has the scope to deliver a broad immune-oncology platform. "Significant milestone" The company has initiated the treatment of the first patient in the second dose cohort in City of Hope’s Phase 1 clinical trial evaluating the safety and tolerability of its CLTX CAR T) cell therapy. This milestone marks the introduction of dual routes of administration of CLTX CAR T cells with both intracranial intratumoral (ICT) and intracranial intraventricular (ICV) dosing. Chow added: “We are very encouraged by the continued progress of the trial, moving to this important next phase with dose escalation and dual routes of administration. “This is another significant milestone in the development of this important therapy for patients with progressive or recurrent glioblastoma.” City of Hope’s Phase 1 clinical trial is expected to enrol 18 to 36 patients with MMP2+ progressive or recurrent glioblastoma over a 24-month period. CLTX CAR T therapy CLTX CAR T cell therapy is a potentially best-in-class CAR T cell therapy that has the potential to address the high unmet medical need of patients with recurrent/progressive GBM. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope. CLTX has been shown in preclinical models to bind more broadly and specifically to GBM cells than other targets like EGFR, HER2 or IL13Rα2. In preclinical models, CLTX CAR T cells also demonstrated potent antitumor activity against GBM while not exhibiting any off-tumour recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile. CLTX CAR T abstract at ASCO meeting Chimeric Therapeutics had the first CLTX CAR T abstract accepted for presentation at the prestigious annual meeting of the American Society of Clinical Oncology (ASCO) in early June. The abstract highlights City of Hope’s phase 1 clinical trial design and objectives for CLTX CAR T. GBM an unmet medical need GBM accounts for 60% of brain tumours in adults and has a poor prognosis with a five-year survival of only 5.1% and a median overall survival of 10 months. According to the National Cancer Institute, there are around 23,820 cases per year of brain and other nervous system cancers in the US, and another 64,600 in Europe, according to the International Agency for Research on Cancer. In its research report in January, Edison noted that if the program yields positive data, the US Food and Drug Administration (FDA) may grant a breakthrough therapy designation (BTD), which would help accelerate the program development. There are 15 separate active trials within GBM using CAR T but only five are sponsored by companies while the rest are at the academic stage. Further Chimeric is only one of two companies outside of China, leading the broker to think that Chimeric has the opportunity to be a leader in this area if it advances the CLTX-CAR T program. Future direction Results from this first-in-human Phase 1 study are expected to demonstrate the safety and feasibility of dual delivery of CLTX-CAR T cells in patients with recurrent or progressive GBM. The Phase 1 study will also determine the maximum tolerated dose and the recommended Phase 2 dosing plan.
↧
Despite new border measures, a record number of migrants fled to U.K. this year
Despite new border measures in Europe, a record high of approximately 10,000 migrants crossed the English Channel to get to the United Kingdom so far this year.
↧
↧
Global Energy Ventures signs MoU to support green hydrogen export project
Global Energy Ventures Ltd (ASX:GEV) has entered into a non-binding, non-exclusive Memorandum of Understanding (MoU) with Province Resources Ltd and Total Eren to support a technical and commercial feasibility study on the export of green hydrogen from the HyEnergy Project. GEV is an energy transition company that aims to deliver compressed shipping solutions for transporting energy to regional markets and its business model is to build, own and operate the production, storage and shipping of green hydrogen. The MoU is intended to provide for GEV to assist Province and Total Eren in evaluating the technical and commercial feasibility of exporting green hydrogen from their HyEnergy Project. This is designed to instil the project partners with enough confidence to warrant the selection of compressed hydrogen as a preferred export method in the next phase of project engineering. The MoU is a win-win scenario for all parties as PRL and Total Eren look to develop a major green hydrogen project located in the Shire of Carnarvon, in the Gascoyne region of Western Australia in close proximity to multiple Asian markets. “The HyEnergy Project is an ideal green hydrogen export project for our compressed hydrogen shipping solution given its strategic location on the WA Gascoyne coastline, within a regional distance to multiple Asian markets with a future requirement for imported hydrogen,” GEV managing director and CEO Martin Carolan said. According to Province CEO David Frances, “The HyEnergy Project partners are keen to understand the benefits of compressed hydrogen in relation to other means of transporting our potential green hydrogen product to market. GEV are leaders in this technology and will bring that experience to the study.” The scope of the MoU includes transport from the project’s onshore hydrogen gas production facility to an offshore ship loading buoy and then on to nominated Asia-Pacific markets utilising GEV’s compressed hydrogen shipping solution. This project could also receive broader support from the Western Australian Government as its Renewable Hydrogen Strategy is focused on developing the hydrogen industry in the state. The WA Government has already outlined its support for these types of projects via its Renewable Hydrogen Roadmap which indicates how the government will support the development of the industry. This feasibility study into the HyEnergy Project is looking at the potential to develop up to an 8GW Renewable power facility and downstream hydrogen facility, The HyEnergy Project is to be developed in phases: the renewable energy capacity will be owned by Total Eren and downstream assets will be equally owned (50/50) by Total Eren and Province. A scoping study is being completed, with a completion date slated for later this year. About GEV In 2020, GEV introduced the world’s first large-scale Compressed Hydrogen (C-H2) ship and positioned the company as an early-mover to fast track the marine transport of Hydrogen. The engineering and design of the C-H2 ship has benefited from GEV’s long-standing history in developing compressed gas carriers through to final construction approval. GEV has demonstrated that the simplicity and energy efficiency of its C-H2 shipping solution is ideally suited for exporting hydrogen over medium distances (ie, Australia to Asia-Pacific, or MENA to Europe) providing a lower delivered cost and eliminating the technical barriers of other transport alternatives.
↧
Distressed debt fund SVP eyes tilt to virus-hobbled Europe
Region likely to throw up opportunities for funds focusing on shaky corporate debt, SVP founder says
↧
Pandemic plunges families into food poverty in world’s rich economies
First increase in food insecurity in Europe and North America since UN data began in 2014
↧
Tech Mahindra to cut dependence on Indian talent base
Tech Mahindra is looking to ramp up hiring in its delivery centres across eastern Europe and Latin America over the next few years to diversify its talent base and provide a buffer against the war for talent currently going on in India.
↧
↧
Philip Morris lifts Vectura offer to $1.4 billion, trumping Carlyle Europe bid
↧
Supersonic Swisspod to Be Tested at Europe’s Groundbreaking Hyperloop Test Track
Will hyperloops rise to the top of future means of transportation? Some say they are in a category of their own, “the fifth transportation mode”. What’s certain is that they are a zero-emission alternative to airplanes, while also being much faster than trains – so they bring the best of these two types of vehicles. There are several hyperloop projects currently under developmen... (continue reading...)
↧
Champions League group stage draw: Date and start time, how to watch and pots for Chelsea, Man City, Man United and Liverpool
The Champions League group stage draw will be decided soon as Chelsea begin their title defence. The Blues beat Premier League rivals Manchester City in the final of last season’s elite competition with Kai Havertz scoring the winner in Porto. Now, those two and the rest of Europe’s best are ready to go again and […]
↧
Europa League group stage draw: Date and start time, how to watch and pots for Leicester and West Ham
Leicester and West Ham will learn their Europa League group stage opponents soon as this season’s competition gets up and running. Villarreal beat Manchester United to European glory last term, winning on penalties after David de Gea fluffed his spot kick. The qualifying rounds are still ongoing across Europe and several teams are still looking […]
↧
↧
Where to get hospitality tickets to see Chelsea at Stamford Bridge
Watch the Champions of Europe in style with these new all-inclusive package deals
↧
Japanese FUSO Canter Truck Now Available in Europe, Boasts Major New Upgrades
The venerable FUSO Canter truck (it’s been around since 1963) is finally making its way from Japan to Europe. It even rocks a whole range of new features, from a change of look and upgraded comfort, to advanced safety technology. Daimler Trucks announced that the famous truck made by its subsidiary, (continue reading...)
↧
Aston Villa told they could have snapped up 'signing of the summer'
Danny Ings left Southampton for a fee of £30million this summer as Aston Villa continue to build an attacking force capable of firing the club into Europe this season
↧
Vodafone’s Europe roaming charges: What does it mean for my phone bill?
Vodafone is the second major UK mobile network to bring back charges for customers who travel to Europe.
↧
↧
Vodafone to bring back roaming charges from January
It follows EE's decision to reintroduce daily charges for using phone tariffs while in Europe
↧
Fires in Greece: The Latest
Wildfires were still burning in Turkey and other parts of Europe, where a protracted heat wave has created tinderbox conditions.
↧
Mobile roaming charges in Europe: What you need to know
How much more will Britons have to pay to use their mobiles in Europe, now the UK has left the EU?
↧
Vodafone to reintroduce roaming charges for UK customers in Europe
Vodafone will reintroduce roaming charges for UK customers who travel in mainland Europe from next year.
↧
↧
Vodafone reintroduces roaming charges when travelling across Europe
The post-Brexit blow means customers will have to pay up to £2 per day to use their monthly allowance of data, calls and texts
↧
Heavy rain and flooding to be more ‘intense and frequent’ in Europe – UN report
Heavy precipitation and flooding will become “more intense and frequent” in Europe due to climate change, a UN report has warned.
↧
Bragg Gaming Group says ORYX Gaming granted a license to supply its exclusive content via its proprietary remote games server to operators in Greece
Bragg Gaming Group Inc. said that its wholly-owned subsidiary ORYX Gaming has been granted a license to supply its exclusive content via its proprietary remote games server to operators in Greece by the Hellenic Gaming Commission. Bragg noted that ORYX is now live and fully compliant in the jurisdiction, which has moved from an interim framework to become fully regulated, in line with a general trend among European countries in recent years. The A1 license enables ORYX to supply its Greek licensed customers including OPAP, Stoiximan, Betsson and NetBet, with more online casino brands expected to go live in the market via the company’s ORYX Hub distribution platform this year. READ: Bragg Gaming Group subsidiary Wild Streak Gaming to develop another four games with International Game Technology In a statement, Chris Looney, chief commercial officer at Bragg commented: “Greece has the potential to become an important market for the group and this license underpins our commitment to our customers in the jurisdiction and represents a new milestone for us in our plans for expansion in regulated markets in Europe, North America and globally. “Our technology is flexible, and it gives us the agility to adapt quickly to new market regulations, and we look forward to launching in many more new markets over the coming quarters with our in-house developed content, our player engagement tools and exclusive third-party content. We have a superb new roadmap of exclusive games coming up, including an increasing proportion from our own in-house studios, and we can't wait to bring them to Greek slots fans.” ORYX is already licensed in Malta and Romania, and is otherwise certified or approved to offer its content in multiple jurisdictions including Sweden, Denmark, Spain, Portugal, Czech Republic, Croatia, Serbia, Switzerland, Gibraltar, Estonia, Latvia, Colombia and, once the market opens as anticipated in Q4 2021, the Netherlands. It is in the process of obtaining further licenses in the UK, Belgium and in the US states of New Jersey, Pennsylvania and Michigan, and is in the process of obtaining certification to supply in Italy. Bragg Gaming is a growing global gaming technology and content group and owner of leading B2B companies in the iGaming industry. Since its inception in 2018, Bragg has grown to include operations across Europe, North America and Latin America and is expanding into an international force within the global online gaming market. Through its wholly-owned subsidiary ORYX Gaming, Bragg delivers proprietary, exclusive and aggregated casino content via its in-house remote games server (RGS) and ORYX Hub distribution platform. ORYX offers a full turnkey iGaming solution, including its Player Account Management (PAM) platform, as well as managed operational and marketing services. Nevada-based Wild Streak Gaming is Bragg's wholly-owned premium US gaming content studio. Wild Streak has a popular portfolio of casino games that are offered across land-based, online and social casino operators in global markets including the US and the UK. In May 2021, Bragg announced its planned acquisition of Nevada-based Spin Games, B2B gaming technology and content provider currently servicing the US market. Spin holds licenses in key iGaming-regulated US states and supplies Tier 1 operators in the region. Contact the author at jon.hopkins@proactiveinvestors.com
↧
Vodafone confirms it will bring back mobile phone roaming charges in Europe from January
The move follows EE’s announcement in June to reintroduce charges.
↧
↧
Why Aston Villa's man in the shadows could be the key to a push for Europe
Morgan Sanson is yet to capture the hearts of Aston Villa , fans. After being given the number 8 for this season however, he could play a major part in Villa’s European ambitions.
↧
Deutsche Telekom to store Celo tokens on Coinbase Custody
Europe’s largest telecoms company by revenue has tapped Coinbase Custody for its Celo tokens.
↧
US stocks open lower amid rising bond yields, dollar strength, lower commodity prices
10.15am: Cautious start to Monday As expected, US equities opened lower on balance on Monday as commodity prices weakened and bond yields and the dollar rose following Friday's stronger than forecast July non-farm payrolls. After 45 minutes of trading, the Dow Jones industrial average was down 146 points, or 0.4% at 35,061, while the broader S&P 500 index shed 0.2%, though the tech-laden Nasdaq Composite ticked 0.01% higher. Craig Erlam, senior market analyst at OANDA Europe commented: "The action has been saved for the commodities corner of the markets in early trade, with gold and silver seeing a meltdown early in Asia before recouping the bulk of the losses in the following hours as bargain hunters seized on the opportunity to get the week off to a good start. "Meanwhile, oil prices have tumbled again as the spread of delta and restrictions that come with it, particularly in China, is causing real concern. We're seeing surges in a variety of countries which will likely weigh on the recovery in the coming months, just as it was starting to gather pace." Erlan added: "The US jobs report on Friday has solidified expectations for a taper announcement this year, most likely September if the August report is another knockout, so now it's all about gathering clues as to when it will start and at what pace. "The Jackson Hole event later this month is the one we've all got circled in the calendar, with numerous Fed speakers appearing, including Chairman Jerome Powell. This is when we could get the strongest hints to date on the timing and pace. Before that, every data point will be scrutinized, starting with the CPI inflation releases on Wednesday. Today we'll hear from Fed voters Raphael Bostic and Thomas Barkin. Commentary from policy makers is getting increasing amounts of attention and I expect that to be the case on a quiet day like today." 6.45am: Weakness expected as new week begins US stocks are expected to open slightly lower on Monday, edging back from last week's record highs as a drop in commodity prices indicated some investor unease about the strength of the economic recovery in spite of Friday's stronger than forecast July non-farm payrolls. Futures for the Dow Jones Industrial Average ticked 0.2% lower, while futures for the broader S&P 500 index also shed 0.2%, and Nasdaq-100 futures were relatively flat. Benchmark Brent crude oil prices dropped nearly 4% on a UN climate change warning as China introduced new virus clampdown measures. Meanwhile, gold and silver prices briefly fell before recovering most of the lost ground amid rising bond yields and strength in the dollar folllowing the latest jobs report which is expected to lead to a tapering by the Federal Reserve sooner rather than later. Investors also have the ongoing earnings season to keep an eye on, with Tyson Foods and vaccine developer BioNTech scheduled to report ahead of the New York opening bell, while AMC Entertainment is expected to post earnings after the markets close. Household names such as Walt Disney and Airbnb are also scheduled to report later this week. A JOLTS report on job openings in June will also be eyed for more information on the labor market. Five things to watch on Monday: Berkshire Hathaway shares rose pre-market after reporting higher net earnings driven by growth at its railroad, utilities and energy companies over the weekend. Barrick Gold said it was on track to achieve its full-year production forecast, after the gold miner reported a 1.2% rise in second-quarter adjusted profit from the first on the back of higher prices for the yellow metal. Amazon.com and Walmart's Flipkart must face antitrust investigations ordered against them in India, the country's Supreme Court ruled on Monday, in a blow to the leading e-commerce giants which had urged judges to quash the inquiries. National Australia Bank has said it will buy Citigroup's local consumer unit for about $882.24 million, as the American bank exits the region while buy-now, pay-later rivals challenge the old credit card business model. Germany's Delivery Hero has taken around a 5% stake in online food delivery rival Deliveroo driving the UK company's share price to its highest since listing on the stock market in March.
↧
Will Tunisia's political crisis affect migration numbers to Europe?
Some believe there is no future in Europe. For others, Kais Saied’s recent power grab will persuade people to stay.
↧
↧
Hungary: Thousands swim across largest lake in central Europe
The 39th Balaton cross swimming takes place on the largest lake in central Europe.
↧
Latvia to declare Belarus border emergency, UK tightens sanctions
Tensions with Europe continue to rise one year on from Lukashenko’s re-election
↧
Ghana Chosen As Headquarters For The Secretariat Of Côte d’Ivoire-Ghana Cocoa Initiative
After several negotiations, Ghana and Côte d’Ivoire have finally signed an agreement to establish a joint Secretariat to be known as the Côte d’Ivoire – Ghana Cocoa Initiative with its headquarters location in Accra, the capital city of Ghana. The agreement sends a strong signal to the international cocoa market that the mutual interests of the cocoa giants are now formalized. Both leading cocoa-producing countries are in West Africa. Within the framework of the agreement, the Secretariat will oversee planning and execution of multiple functions aim at maximizing cocoa production, processing and consumption as well as exports to foreign markets. It will also implement future agenda.
The Steering Committee is the highest decision-making body of the initiative. It is responsible for formulating rules and regulations, ensuring the smooth implementation of the charter and functioning of the Secretariat, approve all budgets and work programs of the Initiative, approve the rights and responsibilities of member countries and resolve conflicts among the member countries.
Both countries have settled on the Director of Corporate Affairs for Europe and Africa at Mars Inc, Alex Arnaud Assanavo as the first Executive Secretary of the Côte d’Ivoire – Ghana Cocoa Initiative.
Speaking at the event, the Chief Executive of Ghana Cocoa Board (COCOBOD), Joseph Boahen Aidoo explained that the Initiative would be the “mouthpiece of Ghana and Côte d’Ivoire in terms of all cocoa matters.”
He said the headquarters agreement was signed in fulfillment of providing a permanent Secretariat “to give effect to the physical presence of the initiative” as well as to give legitimacy to the existence of the headquarters in Accra, Ghana.
Ghana together with the Ivorian government, through the Initiative, are committed to focus on supporting cocoa farmers with improved incomes, harmonize the interests of the two neighboring West African cocoa producing giants at the international level and are very optimistic to raise the situation in the cocoa sector in both countries.
Officials of two cocoa regulatory bodies, Ghana Cocoa Board and Conseil du Cafe Cacao are already handling issues relating to the sustainability of cocoa production, research and marketing of cocoa from both countries.
In order to achieve the objectives of the new Initiative, the secretariat and its staff be accorded diplomatic privileges and offered support to ensure the effective operation of the organization.
Dr Owusu Afriyie Akoto, elected the first Chairman of the Steering Committee of the Ghana-Côte d’Ivoire Cocoa Initiative, described the meeting as historic and important since it sought to ensure the realization of the vision of President Nana Addo Dankwa Akufo-Addo and President Alassane Ouattara.
With the Africa Continental Free Trade Area (AfCFTA) also situated in Accra, it is further expected that interest of foreign investors will be attracted to the country and the West Africa region. According to official reports, Cameroon and Nigeria might also join the Initiative. Ghana and Côte d’Ivoire, the two West African neighbors, jointly account for about 70% of the world’s cocoa output. Ghana and Côte d’Ivoire are located on the coast in West Africa.
↧
Massive Fire Rages Through Greek Island, Prompts More Evacuations
Watch VideoFirefighters and residents battled a massive forest fire on Greece’s second largest island for a seventh day Monday, fighting to save what they can from flames that have decimated vast tracts of pristine forest, destroyed homes and businesses and sent thousands fleeing.The smoke and ash from the fire on Evia, a rugged island of forests and coves almost touching the Greek mainland, blocked out the sun, turning the sky orange as the blaze rampaged across the northern part of the island.
The fire, which began Aug. 3, is the most severe of dozens that have broken out across Greece in the past week, after the country was baked by its worst heat wave in three decades which sent temperatures soaring over 110 degrees for days.
Other big fires have been burning forests and farmland in the southern Greek region of the Peloponnese, while a major blaze that encroached into the northern suburbs of Athens and Mount Parnitha national park on the fringes of the capital was on the wane. Firefighting efforts continued in Parnitha, where French, Israeli and Cypriot firefighters were helping their Greek colleagues.
*SEE MORE: U.N. Report Says Global Warming Is Nearing Limits*
The wildfires have stretched Greece’s firefighting capabilities to the limit, and the government has appealed for help from abroad. More than 20 countries in Europe and the Middle East have responded, sending planes, helicopters, vehicles and manpower.
Despite the help, many residents and local officials have complained of a lack of firefighters, and some have taken to calling in to Greek television networks to appeal for help, particularly from water-dropping planes and helicopters.
Greek authorities, scarred by a deadly wildfire in 2018 near Athens that killed more than 100 people, have emphasized saving lives in their firefighting efforts, sending dozens of evacuation orders for inhabited areas and using ships to get people from coastal areas when necessary.
The coast guard said a total of 2,770 people had been evacuated by sea from fires across the country between July 31 and Aug. 8.
Additional reporting by the Associated Press.
↧
↧
Deutsche Telekom gives Coinbase the custody rights to its Celo
Europe’s biggest Telecom provider Deutsche Telekom has selected US crypto exchange giant Coinbbase to act as the custody for its CELO tokens (CELO/USD). According to the announcement, the exchange will hold the tokens through its custody platform, Coinbase Custody. The telecommunications giant said it was an easy decision to choose the crypto exchange because of […]
↧
US stocks mixed midday on global growth concerns
12.10pm: Dow and S&P 500 fall as weakness in key commodities weigh US stocks were mixed in noon trading as worries over surging coronavirus (COVID-19) Delta variant cases sent West Texas intermediate (WTI) crude oil down as much as 4%, while copper, silver and gold futures each moved lower by at least 1%. The Dow Jones Industrial Average eased 63 points, or 0.2%, to 35,146, while the broader-based S&P 500 inched 2 points lower, or 0.04%, to 4,434. The tech-heavy Nasdaq, meanwhile, added 33 points, or 0.2%, to stand at 14,869. “Over the past 5 quarters, analysts have significantly underestimated EPS, a trend we expect to continue,” Credit Suisse chief U.S. equity strategist Jonathan Golub said. “We see upside to estimates as empty shelves are restocked and pricing power is maintained. Consumer spending should improve as the unemployment rate drops further, accompanied by higher wages,” Golub added. Notable movers included shares of Moderna Inc, which climbed as much as 11% on prospects of booster vaccines needed to control COVID’s spread, while Tesla Inc shares added more than 2% after an upgrade from Jefferies, which predicted the stock would gain more than 20% over the next 12 months. 10.15am: Cautious start to Monday As expected, US equities opened lower on balance on Monday as commodity prices weakened and bond yields and the dollar rose following Friday's stronger than forecast July non-farm payrolls. After 45 minutes of trading, the Dow Jones industrial average was down 146 points, or 0.4% at 35,061, while the broader S&P 500 index shed 0.2%, though the tech-laden Nasdaq Composite ticked 0.01% higher. Craig Erlam, senior market analyst at OANDA Europe commented: "The action has been saved for the commodities corner of the markets in early trade, with gold and silver seeing a meltdown early in Asia before recouping the bulk of the losses in the following hours as bargain hunters seized on the opportunity to get the week off to a good start. "Meanwhile, oil prices have tumbled again as the spread of delta and restrictions that come with it, particularly in China, is causing real concern. We're seeing surges in a variety of countries which will likely weigh on the recovery in the coming months, just as it was starting to gather pace." Erlan added: "The US jobs report on Friday has solidified expectations for a taper announcement this year, most likely September if the August report is another knockout, so now it's all about gathering clues as to when it will start and at what pace. "The Jackson Hole event later this month is the one we've all got circled in the calendar, with numerous Fed speakers appearing, including Chairman Jerome Powell. This is when we could get the strongest hints to date on the timing and pace. Before that, every data point will be scrutinized, starting with the CPI inflation releases on Wednesday. Today we'll hear from Fed voters Raphael Bostic and Thomas Barkin. Commentary from policy makers is getting increasing amounts of attention and I expect that to be the case on a quiet day like today." 6.45am: Weakness expected as new week begins US stocks are expected to open slightly lower on Monday, edging back from last week's record highs as a drop in commodity prices indicated some investor unease about the strength of the economic recovery in spite of Friday's stronger than forecast July non-farm payrolls. Futures for the Dow Jones Industrial Average ticked 0.2% lower, while futures for the broader S&P 500 index also shed 0.2%, and Nasdaq-100 futures were relatively flat. Benchmark Brent crude oil prices dropped nearly 4% on a UN climate change warning as China introduced new virus clampdown measures. Meanwhile, gold and silver prices briefly fell before recovering most of the lost ground amid rising bond yields and strength in the dollar folllowing the latest jobs report which is expected to lead to a tapering by the Federal Reserve sooner rather than later. Investors also have the ongoing earnings season to keep an eye on, with Tyson Foods (NYSE:TSN) and vaccine developer BioNTech scheduled to report ahead of the New York opening bell, while AMC Entertainment is expected to post earnings after the markets close. Household names such as Walt Disney and Airbnb (NASDAQ:ABNB) are also scheduled to report later this week. A JOLTS report on job openings in June will also be eyed for more information on the labor market. Five things to watch on Monday: Berkshire Hathaway (NYSE:BRK) shares rose pre-market after reporting higher net earnings driven by growth at its railroad, utilities and energy companies over the weekend. Barrick Gold said it was on track to achieve its full-year production forecast, after the gold miner reported a 1.2% rise in second-quarter adjusted profit from the first on the back of higher prices for the yellow metal. Amazon.com and Walmart's Flipkart must face antitrust investigations ordered against them in India, the country's Supreme Court ruled on Monday, in a blow to the leading e-commerce giants which had urged judges to quash the inquiries. National Australia Bank has said it will buy Citigroup's local consumer unit for about $882.24 million, as the American bank exits the region while buy-now, pay-later rivals challenge the old credit card business model. Germany's Delivery Hero (ETR:DHER, OTCQX:DLVHF) has taken around a 5% stake in online food delivery rival Deliveroo driving the UK company's share price to its highest since listing on the stock market in March.
↧
UEFA Super Cup 2021: How To Watch Chelsea Vs. Villareal
The two champions of Europe in the Champions and Europa League meet this week and CBS Sports has you covered.
↧
Protesters demonstrating across Europe against vaccination and the health pass
Protests against COVID health pass were held across Europe on Saturday 7 August.
Studio: euronews (in English)
↧
↧
Why Trump conservatives are embracing Hungary's autocracy
New America CEO Anne-Marie Slaughter and Eurasia Group President Ian Bremmer say that Fox News host Tucker Carlson’s embrace of Hungary’s authoritarian leader Viktor Orbán reflects former..
Studio: Bleacher Report AOL
↧
On GPS: Why some U.S. conservatives love Hungary
The Eurasia Group’s Ian Bremmer, New America’s Anne-Marie Slaughter and Fareed on the affinity between the American right and Viktor Orban’s “anti-globalism.”
Studio: Bleacher Report AOL
↧
French flag in the air as Paris countdown to hosting next Olympic Games
Colors of the French flag in the air as jets fly over the Trocadéro during today’s Olympics Closing Ceremony and handoff to Paris for the next Olympic Games in 2024. VIDEO COURTESY: Brendan..
Studio: Newsvia English
↧
Watch Moment Arsonist Starts Fire in Italian Countryside
A hidden camera captured an arsonist starting a fire in a town outside of Naples, in Italy. Veuer’s Maria Mercedes Galuppo has the story.
Studio: Veuer
↧
↧
COVID-19: Australian local lockdown ends even as Delta variant circulates globally
Here are the latest COVID-19 developments from around the world.
Studio: Euronews English
↧
Will Tunisia's political crisis affect migration numbers to Europe?
Some believe there is no future in Europe. For others, Kais Saied’s recent power grab will persuade people to stay.
Studio: euronews (in English)
↧
Hungary: Thousands swim across largest lake in central Europe
The 39th Balaton cross swimming takes place on the largest lake in central Europe.
Studio: euronews (in English)
↧
Hungary: Thousands swim across largest lake in central Europe
The 39th Balaton cross swimming takes place on the largest lake in central Europe.
Studio: Euronews English
↧
↧
World Climate Scientists Issue Stark Report
Roxana Saberi reports they warn that there will be many more disasters, like this summer's historic flooding in Europe and elsewhere, if nations don't slash greenhouse gas emissions now.
Studio: CBS4 Miami
↧
More Pages to Explore .....
